Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.
Lava Therapeutics, a Netherlands-based cancer immunotherapy developer based on research at Amsterdam University Medical Centers, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2016, Lava is developing bispecific antibody-based treatments intended to treat cancer by activating a subset of T cells known as the Vg9Vd2 cells, which can naturally separate tumour cells and healthy cells, and engaging them to kill cancer cells.
The company’s technology is based on research by…
